Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Oncology
Kimio Yonesaka, Junko Tanizak, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Summary: This study reveals that HER3 expression is augmented in EGFR-mutated NSCLC tumors with acquired EGFR-TKI resistance. The mechanisms underlying HER3 regulation are elucidated, and a rationale for combination therapy with HER3-DXd and EGFR-TKI in EGFR-mutated NSCLC is proposed.
CLINICAL CANCER RESEARCH
(2022)
Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Fan Yang, Chunlan Ma, Jing Qiu, Xiaoli Feng, Kai Yang
Summary: This study identified 114 circRNAs that were differentially expressed in NSCLC tissue compared to paracancerous tissue levels, with 77 downregulated and 37 upregulated. CircRNA_001846 may serve as a promising diagnostic biomarker for NSCLC, associated with tumor differentiation, lymph node metastasis, and node metastasis stage.
Article
Pharmacology & Pharmacy
A. S. Pal, M. Bains, A. Agredo, A. L. Kasinski
Summary: Lung cancer is a major cause of cancer-related deaths, and overcoming resistance to EGFR inhibitors is crucial in the treatment of non-small cell lung cancer. This study identifies the important role of microRNAs in driving resistance to EGFR inhibitors in non-small cell lung cancer cells.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yihong Ren, Yuxin Zhao, Yanan Shan, Sixuan Li, Nan Su, Zhigang Cui, Zhihua Yin
Summary: This study found that hsa_circ_0049657, a circular RNA derived from the NFIX gene, was down-regulated in NSCLC tissues and cells. In addition, we could suppress the proliferation and invasion abilities and promote apoptosis of NSCLC cells by up-regulating hsa_circ_0049657.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mahmoud Toulany, Mari Iida, Konstanze Lettau, John P. Coan, Simone Rebholz, Shayan Khozooei, Paul M. Harari, Deric L. Wheeler
Summary: This study found that radiation-induced activation of nuclear AKT is mainly dependent on the expression of HER3 in non-small cell lung cancer (NSCLC), and HER3 is associated with the tyrosine kinase activation of epidermal growth factor receptor. Targeting HER3 in combination with radiotherapy may be a rational treatment option.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Oncology
Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao, Jie He
Summary: This study provides an overview of the clinical trials on Sintilimab for non-small cell lung cancer (NSCLC) conducted in China, showing its effectiveness and tolerability, but further research is needed.
BIOMARKER RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Przemyslaw Bieganski, Martina Godel, Chiara Riganti, Daniel Fabio Kawano, Joanna Kopecka, Konrad Kowalski
Summary: A library of 1,4- and 1,5-triazole ferrocenyl derivatives of erlotinib were synthesized and their anticancer activity was studied against erlotinib-sensitive and erlotinib-resistant lung cancer cells. Among the compounds investigated, two isomers showed superior activity against erlotinib-resistant cells, with a mechanism of action different from erlotinib.
BIOORGANIC CHEMISTRY
(2022)
Article
Oncology
Xinan Wang, Biagio Ricciuti, Tom Nguyen, Xihao Li, Michael S. Rabin, Mark M. Awad, Xihong Lin, Bruce E. Johnson, David C. Christiani
Summary: This study investigates the relationship between smoking history and clinically relevant mutations in lung cancer patients, revealing a significant dose-response association between smoking history and genetic alterations in cancer-related pathways and tumor mutation burden in advanced lung adenocarcinoma.
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Review
Immunology
Yang Ge, Ting Ye, Siyun Fu, Xiaoying Jiang, Hang Song, Bin Liu, Guoquan Wang, Jinghui Wang
Summary: Lung cancer, especially non-small cell lung cancer (NSCLC), is a severe and common type of cancer worldwide. NSCLC is typically treated with surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. However, immunotherapy still faces challenges, such as poor response rates and uncertainty in identifying effective populations. This review focuses on the role of extracellular vesicles (EVs) as biomarkers in NSCLC immunotherapy and discusses their definition, properties, and different components as potential biomarkers. It also explores the interaction between EVs as biomarkers and novel approaches or concepts in NSCLC immunotherapy research, providing insights for improving the benefits of immunotherapy for NSCLC patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Hang Yan, Shengjie Tang, Shoujun Tang, Jun Zhang, Haiyang Guo, Chao Qin, Haiyang Hu, Chuan Zhong, Li Yang, Yunhe Zhu, Haining Zhou
Summary: Non-small cell lung cancer (NSCLC) is a common malignant tumor with suboptimal clinical success due to late diagnosis, limited treatment options, high recurrence rates, and drug resistance. MicroRNAs (miRNAs), small non-coding RNAs, have emerged as important players in NSCLC initiation, progression, and drug resistance. This review provides an overview of miRNA dysregulation and resistance in NSCLC and discusses their potential applications in different anti-cancer treatments.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)